(NASDAQ: JANX) Janux Therapeutics's forecast annual revenue growth rate of 227.71% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.89%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.67%.
Janux Therapeutics's revenue in 2025 is $9,336,000.On average, 1 Wall Street analysts forecast JANX's revenue for 2027 to be $1,990,652,281, with the lowest JANX revenue forecast at $1,990,652,281, and the highest JANX revenue forecast at $1,990,652,281. On average, 3 Wall Street analysts forecast JANX's revenue for 2028 to be $8,448,792,216, with the lowest JANX revenue forecast at $6,348,310,843, and the highest JANX revenue forecast at $12,088,892,824.
In 2029, JANX is forecast to generate $19,930,192,878 in revenue, with the lowest revenue forecast at $1,670,514,682 and the highest revenue forecast at $42,982,467,039.